Biosimilars – Forecast – Oncology
In 2021, sales of branded MAb biologics in oncology exceeded $36 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5 billion. Throughout the 2021-2031 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Oncology
- Market forecast in the major pharmaceutical markets
- Major-market forecast: oncology MAbs
- Oncology MAb terminology
- G-CSF terminology
- Major-market forecast: G-CSFs
- Overarching forecast assumptions
- Overview of oncology MAb brands in the forecast
- Biosimilar entry assumptions for oncology MAbs
- Overview of assumptions regarding biosimilars of oncology MAbs
- Overview of G-CSF brands in the forecast
- Overview of approved G-CSF brands
- Biosimilar entry assumptions for G-CSF brands
- Overview of assumptions regarding biosimilars of G-CSFs
- United States
- Europe
- Japan
- Overview of oncology MAb brands in the forecast
- Drug-specific forecast assumptions
- Avastin
- Outlook for Avastin
- First biosimilars of Avastin in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Avastin sales forecast in the United States: 2021-2031
- Avastin sales forecast in the EU5: 2021-2031
- Avastin sales forecast in Japan: 2021-2031
- Cyramza
- Outlook for Cyramza
- First biosimilars of Cyramza in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Cyramza sales forecast in the United States: 2021-2031
- Cyramza sales forecast in the EU5: 2021-2031
- Cyramza sales forecast in Japan: 2021-2031
- Erbitux
- Outlook for Erbitux
- First biosimilars of Erbitux in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Erbitux sales forecast in the United States: 2021-2031
- Erbitux sales forecast in the EU5: 2021-2031
- Erbitux sales forecast in Japan: 2021-2031
- Darzalex
- Outlook for Darzalex
- First biosimilars of Darzalex in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Darzalex sales forecast in the United States: 2021-2031
- Darzalex sales forecast in the EU5: 2021-2031
- Herceptin
- Outlook for Herceptin
- First biosimilars of Herceptin in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Roche's strategies to protect its HER2 franchise
- Herceptin sales forecast in the United States: 2021-2031
- Herceptin sales forecast in the EU5: 2021-2031
- Herceptin sales forecast in Japan: 2021-2031
- Kadcyla
- Outlook for Kadcyla
- First biosimilars of Kadcyla in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Kadcyla sales forecast in the United States: 2021-2031
- Kadcyla sales forecast in the EU5: 2021-2031
- Kadcyla sales forecast in Japan: 2021-2031
- Keytruda
- Outlook for Keytruda
- First biosimilars of Keytruda in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Keytruda sales forecast in the United States: 2021-2031
- Keytruda sales forecast in the EU5: 2021-2031
- Opdivo
- Outlook for Opdivo
- First biosimilars of Opdivo in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Opdivo sales forecast in the United States: 2021-2031
- Opdivo sales forecast in the EU5: 2021-2031
- Opdivo sales forecast in Japan: 2021-2031
- Perjeta
- Outlook for Perjeta
- First biosimilars of Perjeta in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Perjeta sales forecast in the United States: 2021-2031
- Perjeta sales forecast in the EU5: 2021-2031
- Perjeta sales forecast in Japan: 2021-2031
- Rituxan / MabThera
- Outlook for Rituxan / MabThera
- First biosimilars of Rituxan in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Roche's strategies to protect its CD20 franchise
- Rituxan sales forecast in oncology for the United States: 2021-2031
- MabThera sales forecast in oncology for the EU5: 2021-2031
- Rituxan sales forecast in oncology for Japan: 2021-2031
- Rituxan sales forecast for the United States (immunology and oncology): 2021-2031
- MabThera sales forecast for the EU5 (immunology and oncology): 2021-2031
- Vectibix
- Outlook for Vectibix
- First biosimilars of Vectibix in the major pharmaceutical markets
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Vectibix sales forecast in the United States: 2021-2031
- Vectibix sales forecast in the EU5: 2021-2031
- Vectibix sales forecast in Japan: 2021-2031
- Yervoy
- Outlook for Yervoy
- First biosimilars of Yervoy in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Yervoy sales forecast in the United States: 2021-2031
- Yervoy sales forecast in the EU5: 2021-2031
- Yervoy sales forecast in Japan: 2021-2031
- Neupogen / Gran
- Outlook for Neupogen / Gran
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilars uptake assumptions
- Neupogen sales forecast in the United States: 2021-2031
- Neupogen sales forecast in the EU5: 2021-2031
- Gran sales forecast in Japan: 2021-2031
- Neulasta / G-Lasta
- Outlook for Neulasta / G-Lasta
- First biosimilars of Neulasta / G-Lasta in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Biosimilar uptake assumptions
- Biosimilar and brand net cost assumptions
- Neulasta sales forecast in the United States: 2021-2031
- Neulasta sales forecast in the EU5: 2021-2031
- G-Lasta sales forecast in Japan: 2021-2031
- Avastin
- Market forecast in the major pharmaceutical markets
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.
